U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07152041) titled 'Newly-diagnosed Pediatric Ph-positive B-ALL Protocol' on March 28.
Brief Summary: This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol
Study Start Date: March 28
Study Type: INTERVENTIONAL
Condition:
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positiv...